IL15 and prostate neoplasm: The in vivo investigation of the efficacy of IL-15 showed that only cytotopically modified IL-15 in doses equal or higher to 5 μg led to both a significant growth delay of TRAMP-C2 prostate tumors and an increase in mice survival compared with control.